Concepts (284)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Incontinence, Stress | 12 | 2019 | 196 | 2.920 |
Why?
|
| Prostatectomy | 14 | 2016 | 476 | 2.640 |
Why?
|
| Postoperative Complications | 20 | 2017 | 2275 | 2.360 |
Why?
|
| Urethra | 7 | 2020 | 115 | 2.330 |
Why?
|
| Urinary Sphincter, Artificial | 8 | 2019 | 14 | 2.050 |
Why?
|
| Prostatic Hyperplasia | 11 | 2016 | 91 | 2.050 |
Why?
|
| Penis | 5 | 2015 | 60 | 1.780 |
Why?
|
| Reoperation | 7 | 2017 | 598 | 1.600 |
Why?
|
| Botulinum Toxins, Type A | 6 | 2017 | 50 | 1.470 |
Why?
|
| Urethral Diseases | 3 | 2015 | 15 | 1.310 |
Why?
|
| Urinary Bladder | 10 | 2020 | 246 | 1.310 |
Why?
|
| Risk Assessment | 6 | 2016 | 2290 | 1.300 |
Why?
|
| Patient Readmission | 4 | 2017 | 351 | 1.290 |
Why?
|
| Neuromuscular Agents | 5 | 2017 | 26 | 1.280 |
Why?
|
| Urologic Diseases | 6 | 2016 | 44 | 1.200 |
Why?
|
| Cystectomy | 8 | 2016 | 105 | 1.160 |
Why?
|
| Ureter | 4 | 2016 | 93 | 1.150 |
Why?
|
| Urinary Bladder, Overactive | 4 | 2017 | 90 | 1.120 |
Why?
|
| Suburethral Slings | 5 | 2016 | 75 | 1.110 |
Why?
|
| Sex Reassignment Surgery | 3 | 2017 | 40 | 1.100 |
Why?
|
| Penile Prosthesis | 4 | 2017 | 24 | 1.090 |
Why?
|
| Penile Diseases | 2 | 2015 | 8 | 1.020 |
Why?
|
| Intraoperative Complications | 2 | 2016 | 188 | 0.970 |
Why?
|
| Urinary Diversion | 5 | 2016 | 42 | 0.950 |
Why?
|
| Robotic Surgical Procedures | 3 | 2016 | 304 | 0.820 |
Why?
|
| Urinary Retention | 4 | 2014 | 42 | 0.790 |
Why?
|
| Laparoscopy | 8 | 2016 | 771 | 0.760 |
Why?
|
| Urologic Surgical Procedures | 9 | 2017 | 147 | 0.740 |
Why?
|
| Urinary Incontinence | 6 | 2014 | 213 | 0.710 |
Why?
|
| Urethral Stricture | 2 | 2015 | 14 | 0.710 |
Why?
|
| Abdominal Cavity | 1 | 2020 | 18 | 0.700 |
Why?
|
| Replantation | 2 | 2016 | 36 | 0.670 |
Why?
|
| Male | 53 | 2020 | 42251 | 0.650 |
Why?
|
| Humans | 77 | 2020 | 89063 | 0.610 |
Why?
|
| Incontinence Pads | 2 | 2016 | 4 | 0.600 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2016 | 251 | 0.580 |
Why?
|
| Pelvic Organ Prolapse | 2 | 2017 | 154 | 0.580 |
Why?
|
| Suture Anchors | 1 | 2017 | 5 | 0.580 |
Why?
|
| Pubic Bone | 1 | 2017 | 9 | 0.580 |
Why?
|
| Urination | 3 | 2016 | 37 | 0.580 |
Why?
|
| Electric Stimulation Therapy | 1 | 2017 | 46 | 0.570 |
Why?
|
| Ureteral Diseases | 1 | 2016 | 14 | 0.550 |
Why?
|
| Surgical Wound | 1 | 2016 | 6 | 0.550 |
Why?
|
| Prosthesis Implantation | 2 | 2017 | 126 | 0.540 |
Why?
|
| Free Tissue Flaps | 1 | 2017 | 49 | 0.540 |
Why?
|
| Surgical Flaps | 3 | 2014 | 249 | 0.530 |
Why?
|
| Middle Aged | 36 | 2020 | 25863 | 0.520 |
Why?
|
| Surgically-Created Structures | 1 | 2015 | 5 | 0.510 |
Why?
|
| Hysterectomy | 1 | 2016 | 151 | 0.500 |
Why?
|
| Mouth Mucosa | 1 | 2015 | 67 | 0.490 |
Why?
|
| Follow-Up Studies | 19 | 2016 | 3657 | 0.480 |
Why?
|
| Aged | 33 | 2020 | 19077 | 0.480 |
Why?
|
| Urinary Bladder Neck Obstruction | 5 | 2015 | 21 | 0.480 |
Why?
|
| Urinary Tract Infections | 4 | 2017 | 76 | 0.420 |
Why?
|
| Urinary Bladder Diseases | 4 | 2008 | 41 | 0.420 |
Why?
|
| Quality Improvement | 1 | 2016 | 447 | 0.410 |
Why?
|
| Female | 32 | 2020 | 46011 | 0.400 |
Why?
|
| Urodynamics | 7 | 2020 | 122 | 0.400 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2016 | 395 | 0.380 |
Why?
|
| Treatment Outcome | 16 | 2016 | 8203 | 0.370 |
Why?
|
| Aged, 80 and over | 16 | 2017 | 6777 | 0.370 |
Why?
|
| Risk Factors | 8 | 2016 | 5466 | 0.360 |
Why?
|
| Rectus Abdominis | 2 | 2008 | 40 | 0.350 |
Why?
|
| Uterine Prolapse | 2 | 2008 | 80 | 0.340 |
Why?
|
| Surgical Mesh | 2 | 2008 | 122 | 0.340 |
Why?
|
| Cystoscopy | 4 | 2015 | 39 | 0.330 |
Why?
|
| Penile Implantation | 1 | 2009 | 14 | 0.330 |
Why?
|
| Databases, Factual | 4 | 2020 | 850 | 0.320 |
Why?
|
| Prostatism | 1 | 2008 | 5 | 0.320 |
Why?
|
| Transsexualism | 1 | 2009 | 34 | 0.320 |
Why?
|
| Adult | 22 | 2020 | 26507 | 0.310 |
Why?
|
| Botulinum Toxins | 1 | 2008 | 17 | 0.310 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2008 | 15 | 0.310 |
Why?
|
| Vesicovaginal Fistula | 1 | 2008 | 12 | 0.310 |
Why?
|
| Urination Disorders | 1 | 2008 | 50 | 0.310 |
Why?
|
| Sacrum | 2 | 2017 | 43 | 0.290 |
Why?
|
| Prostatic Neoplasms | 6 | 2000 | 1768 | 0.290 |
Why?
|
| United States | 8 | 2017 | 6955 | 0.280 |
Why?
|
| Diagnostic Techniques, Urological | 2 | 2017 | 14 | 0.280 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2008 | 148 | 0.270 |
Why?
|
| Quality of Life | 5 | 2008 | 1662 | 0.270 |
Why?
|
| Iatrogenic Disease | 2 | 2016 | 70 | 0.270 |
Why?
|
| Time Factors | 8 | 2016 | 5320 | 0.270 |
Why?
|
| Cysts | 1 | 2007 | 106 | 0.260 |
Why?
|
| Retrospective Studies | 14 | 2020 | 9003 | 0.260 |
Why?
|
| Prospective Studies | 8 | 2016 | 4273 | 0.260 |
Why?
|
| Urinary Reservoirs, Continent | 2 | 2015 | 14 | 0.260 |
Why?
|
| Fournier Gangrene | 1 | 2005 | 2 | 0.260 |
Why?
|
| Tissue Expansion | 1 | 2005 | 19 | 0.260 |
Why?
|
| Scrotum | 1 | 2005 | 18 | 0.260 |
Why?
|
| Morbidity | 2 | 2016 | 149 | 0.250 |
Why?
|
| Fibula | 1 | 2005 | 32 | 0.250 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2005 | 16 | 0.250 |
Why?
|
| Erectile Dysfunction | 1 | 2005 | 75 | 0.240 |
Why?
|
| Pancreas Transplantation | 1 | 2005 | 104 | 0.240 |
Why?
|
| Device Removal | 2 | 2017 | 167 | 0.220 |
Why?
|
| Administration, Intravesical | 3 | 2008 | 32 | 0.220 |
Why?
|
| Preoperative Care | 3 | 2000 | 396 | 0.220 |
Why?
|
| Hypospadias | 1 | 2002 | 6 | 0.210 |
Why?
|
| Amputation, Traumatic | 1 | 2002 | 9 | 0.210 |
Why?
|
| Urology | 2 | 2001 | 117 | 0.210 |
Why?
|
| Prostate-Specific Antigen | 3 | 2000 | 359 | 0.210 |
Why?
|
| Nephrectomy | 2 | 2015 | 293 | 0.210 |
Why?
|
| Anastomosis, Surgical | 3 | 2016 | 273 | 0.200 |
Why?
|
| Fascia | 1 | 2001 | 30 | 0.200 |
Why?
|
| Incidence | 2 | 2016 | 1592 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2001 | 599 | 0.190 |
Why?
|
| Biofeedback, Psychology | 1 | 2000 | 13 | 0.190 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2000 | 10 | 0.180 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2017 | 77 | 0.180 |
Why?
|
| Exercise Therapy | 1 | 2000 | 81 | 0.180 |
Why?
|
| Pressure | 2 | 2019 | 165 | 0.170 |
Why?
|
| Ureteral Obstruction | 2 | 2002 | 67 | 0.170 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2020 | 67 | 0.160 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 207 | 0.160 |
Why?
|
| Collagen | 1 | 2000 | 293 | 0.160 |
Why?
|
| Diabetes Complications | 1 | 2020 | 170 | 0.160 |
Why?
|
| Cryosurgery | 2 | 1995 | 52 | 0.160 |
Why?
|
| Phytotherapy | 1 | 1999 | 136 | 0.150 |
Why?
|
| Urinary Catheterization | 4 | 2014 | 36 | 0.150 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 1997 | 6 | 0.150 |
Why?
|
| Platinum Compounds | 1 | 1997 | 31 | 0.150 |
Why?
|
| Seminoma | 1 | 1997 | 13 | 0.150 |
Why?
|
| Lymphatic Diseases | 1 | 1997 | 36 | 0.150 |
Why?
|
| Cervix Uteri | 1 | 2017 | 70 | 0.140 |
Why?
|
| Calcitonin Gene-Related Peptide | 2 | 2008 | 40 | 0.140 |
Why?
|
| Postoperative Hemorrhage | 2 | 2016 | 46 | 0.140 |
Why?
|
| Length of Stay | 3 | 2016 | 732 | 0.140 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2016 | 12 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2017 | 229 | 0.140 |
Why?
|
| Creatinine | 1 | 1997 | 293 | 0.140 |
Why?
|
| Testicular Neoplasms | 1 | 1997 | 113 | 0.130 |
Why?
|
| Constriction, Pathologic | 1 | 2016 | 217 | 0.130 |
Why?
|
| Bacterial Infections | 1 | 2017 | 184 | 0.130 |
Why?
|
| Pelvis | 1 | 2016 | 96 | 0.130 |
Why?
|
| Orchiectomy | 1 | 1996 | 72 | 0.130 |
Why?
|
| Operative Time | 1 | 2016 | 142 | 0.130 |
Why?
|
| Anilides | 1 | 1996 | 48 | 0.130 |
Why?
|
| Abdomen | 1 | 2016 | 122 | 0.130 |
Why?
|
| Organ Size | 1 | 2016 | 369 | 0.130 |
Why?
|
| Rupture | 1 | 2015 | 61 | 0.130 |
Why?
|
| Recurrence | 2 | 2016 | 1140 | 0.130 |
Why?
|
| Rhabdomyolysis | 1 | 2015 | 28 | 0.130 |
Why?
|
| Survival Rate | 3 | 2015 | 1889 | 0.130 |
Why?
|
| Steroids | 1 | 2016 | 174 | 0.120 |
Why?
|
| Mortality | 1 | 2016 | 149 | 0.120 |
Why?
|
| Radiotherapy | 2 | 2016 | 331 | 0.120 |
Why?
|
| Age Factors | 3 | 2016 | 1867 | 0.120 |
Why?
|
| Illinois | 1 | 2016 | 472 | 0.120 |
Why?
|
| Linear Models | 1 | 2016 | 421 | 0.120 |
Why?
|
| Androgen Antagonists | 1 | 1996 | 154 | 0.120 |
Why?
|
| Reference Values | 1 | 2016 | 661 | 0.120 |
Why?
|
| Urinary Bladder, Neurogenic | 2 | 2013 | 25 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2013 | 2863 | 0.120 |
Why?
|
| Self Report | 1 | 2016 | 295 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2016 | 278 | 0.120 |
Why?
|
| Urinary Fistula | 1 | 2013 | 7 | 0.110 |
Why?
|
| Ileum | 1 | 2014 | 160 | 0.110 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 280 | 0.110 |
Why?
|
| Kidney Transplantation | 2 | 2005 | 849 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2015 | 386 | 0.110 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2002 | 31 | 0.100 |
Why?
|
| Sepsis | 1 | 2016 | 319 | 0.100 |
Why?
|
| Smoking | 1 | 2016 | 620 | 0.100 |
Why?
|
| Delirium | 1 | 2012 | 72 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 786 | 0.100 |
Why?
|
| Urinary Tract | 2 | 2005 | 35 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2752 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2016 | 780 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 479 | 0.090 |
Why?
|
| Kidney | 1 | 1995 | 1145 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1995 | 1363 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2012 | 865 | 0.080 |
Why?
|
| Ureteroscopy | 2 | 2000 | 38 | 0.080 |
Why?
|
| Stents | 2 | 2002 | 395 | 0.080 |
Why?
|
| Hypertension | 1 | 1994 | 741 | 0.080 |
Why?
|
| Substance P | 1 | 2008 | 61 | 0.080 |
Why?
|
| Topography, Medical | 1 | 2007 | 4 | 0.070 |
Why?
|
| Utilization Review | 1 | 2007 | 23 | 0.070 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 2001 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2016 | 1041 | 0.070 |
Why?
|
| Prosthesis Design | 1 | 2008 | 296 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2008 | 1237 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2007 | 157 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2007 | 234 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2003 | 1837 | 0.070 |
Why?
|
| Valsalva Maneuver | 1 | 2006 | 6 | 0.070 |
Why?
|
| Urinary Tract Physiological Phenomena | 1 | 2005 | 4 | 0.070 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2005 | 16 | 0.070 |
Why?
|
| Prostate | 2 | 2003 | 393 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2014 | 461 | 0.060 |
Why?
|
| Lymph Node Excision | 2 | 1997 | 220 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2411 | 0.060 |
Why?
|
| Duodenum | 1 | 2005 | 103 | 0.060 |
Why?
|
| Internet | 3 | 2001 | 318 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2005 | 235 | 0.060 |
Why?
|
| Lithotripsy | 2 | 2000 | 42 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2003 | 150 | 0.060 |
Why?
|
| Physicians' Offices | 1 | 2003 | 3 | 0.050 |
Why?
|
| Rats | 3 | 2008 | 4040 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2000 | 360 | 0.050 |
Why?
|
| Urinary Bladder Calculi | 1 | 2002 | 2 | 0.050 |
Why?
|
| Finasteride | 1 | 2002 | 8 | 0.050 |
Why?
|
| International Cooperation | 1 | 2003 | 125 | 0.050 |
Why?
|
| Equipment Design | 1 | 2003 | 415 | 0.050 |
Why?
|
| Jejunum | 1 | 2002 | 80 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1855 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2000 | 2612 | 0.050 |
Why?
|
| Elasticity | 1 | 2001 | 96 | 0.050 |
Why?
|
| Tensile Strength | 1 | 2001 | 80 | 0.050 |
Why?
|
| Cadaver | 1 | 2001 | 185 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 988 | 0.050 |
Why?
|
| Postal Service | 1 | 2001 | 17 | 0.050 |
Why?
|
| Observer Variation | 1 | 2003 | 610 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2008 | 758 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2003 | 200 | 0.050 |
Why?
|
| Professional Practice | 1 | 2001 | 46 | 0.050 |
Why?
|
| Ureteral Calculi | 1 | 2000 | 10 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2001 | 343 | 0.050 |
Why?
|
| Cefazolin | 1 | 2000 | 7 | 0.040 |
Why?
|
| Ciprofloxacin | 1 | 2000 | 29 | 0.040 |
Why?
|
| Cephalosporins | 1 | 2000 | 24 | 0.040 |
Why?
|
| Pelvic Floor | 1 | 2000 | 85 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 233 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2001 | 280 | 0.040 |
Why?
|
| Health Surveys | 1 | 2000 | 240 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2001 | 317 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2000 | 91 | 0.040 |
Why?
|
| Hospitals, University | 1 | 1999 | 195 | 0.040 |
Why?
|
| Awareness | 1 | 1999 | 89 | 0.040 |
Why?
|
| Electrocoagulation | 1 | 1997 | 23 | 0.040 |
Why?
|
| Prognosis | 2 | 2015 | 3773 | 0.040 |
Why?
|
| Lasers, Solid-State | 1 | 2016 | 8 | 0.040 |
Why?
|
| Kidney Calculi | 1 | 2000 | 341 | 0.040 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2016 | 32 | 0.040 |
Why?
|
| Tosyl Compounds | 1 | 1996 | 15 | 0.030 |
Why?
|
| Plant Extracts | 1 | 1998 | 245 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1591 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 682 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 2014 | 0.030 |
Why?
|
| Contracture | 1 | 2015 | 18 | 0.030 |
Why?
|
| Nitriles | 1 | 1996 | 160 | 0.030 |
Why?
|
| Chicago | 1 | 1999 | 1423 | 0.030 |
Why?
|
| Renin | 1 | 1994 | 67 | 0.030 |
Why?
|
| Microsurgery | 1 | 2014 | 88 | 0.030 |
Why?
|
| Intestines | 1 | 2016 | 416 | 0.030 |
Why?
|
| Logistic Models | 1 | 1997 | 1212 | 0.030 |
Why?
|
| Endoscopy | 1 | 2016 | 348 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2012 | 25 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 225 | 0.030 |
Why?
|
| Groin | 1 | 2012 | 9 | 0.030 |
Why?
|
| Animals | 4 | 2008 | 27317 | 0.030 |
Why?
|
| Biopsy | 1 | 1994 | 1182 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 684 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 859 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1043 | 0.020 |
Why?
|
| Contrast Media | 1 | 2014 | 1090 | 0.020 |
Why?
|
| Urothelium | 1 | 2008 | 71 | 0.020 |
Why?
|
| Receptors, Purinergic P2X | 1 | 2005 | 1 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2001 | 1710 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 996 | 0.010 |
Why?
|
| Contraindications | 1 | 2000 | 70 | 0.010 |
Why?
|
| Urinary Calculi | 1 | 2000 | 46 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 783 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2001 | 590 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2000 | 240 | 0.010 |
Why?
|
| Acute Disease | 1 | 2001 | 841 | 0.010 |
Why?
|
| Data Collection | 1 | 2000 | 375 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2002 | 948 | 0.010 |
Why?
|
| Life Expectancy | 1 | 1998 | 89 | 0.010 |
Why?
|
| Child | 2 | 2000 | 7149 | 0.010 |
Why?
|
| Robotics | 1 | 2000 | 269 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2000 | 461 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1997 | 121 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1997 | 115 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2000 | 1714 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1996 | 287 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1998 | 1533 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1996 | 502 | 0.010 |
Why?
|
| Infant | 1 | 2000 | 3147 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2000 | 3717 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 1996 | 1214 | 0.010 |
Why?
|
| Hospitalization | 1 | 1997 | 876 | 0.010 |
Why?
|
| Adolescent | 1 | 1997 | 9237 | 0.000 |
Why?
|